Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Q&As & Interviews

Regulation and Policy Interview with Scott Burger, Principal of Advanced Cell and Gene Therapy

Edited by Ben Norris | 10 March 2023
Scott Burger, Principal of Advanced Cell and Gene Therapy, discusses some of the recent trends in regulation and policy surrounding cell and gene therapy development.
https://www.youtube.com/watch?v=oFzMRr2HUUQ

Get your weekly dose of industry news and announcements here, or head over to our Cell portal to catch up with the latest advances in cellular therapies.

Want to receive the latest industry announcements on cell manufacture and development? Sign up for our Cell series newsletter to get up-to-date news each month. If you'd like to know more about our upcoming 3D Cell Culture conference, visit our event website to download an agenda and register your interest.

Speaker Biographies

Scott R. Burger, MD, is the Principal of Advanced Cell and Gene Therapy, a consulting firm specializing in cell and gene therapy product development, manufacturing, and regulatory affairs. Dr. Burger has over 30 years of experience developing cell and gene therapy products and has consulted for over 150 industry and academic clients in North America, Europe, Asia, and Australia. He has directed or consulted on process development, manufacturing, and regulatory aspects of a wide range of cell therapy and gene therapy products, including CAR T-cells, gene-edited cells, dendritic cell vaccines, natural killer (NK) cells, and other immunotherapies, hematopoietic stem cells (HSCs) from bone marrow, blood, umbilical cord blood, and regenerative medicine products such as mesenchymal stem cells (MSCs), chondrocytes, pancreatic islet cells, and other somatic cell therapies.

Related Resources

Cell Therapy for Solid Tumors: An Innovative Approach to Cancer Treatment

Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.
Read More

Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough

The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
01/11/24
Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing